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Gene annotation databases (compendiums maintained by the scientific community that describe
the biological functions performed by individual genes) are commonly used to evaluate the functional
properties of experimentally derived gene sets. Overlap statistics, such as Fishers Exact test (FET),
are often employed to assess these associations, but don’t account for non-uniformity in the number
of genes annotated to individual functions or the number of functions associated with individual
genes. We find FET is strongly biased toward over-estimating overlap significance if a gene set
has an unusually high number of annotations. To correct for these biases, we develop Annotation
Enrichment Analysis (AEA), which properly accounts for the non-uniformity of annotations. We
show that AEA is able to identify biologically meaningful functional enrichments that are obscured
by numerous false-positive enrichment scores in FET, and we therefore suggest it be used to more
accurately assess the biological properties of gene sets.
1. INTRODUCTION
Evaluating the functional properties of gene sets is a
routine step in understanding high-throughput biological
data [1, 2] and is commonly used both to verify that the
genes implicated in a biological experiment are function-
ally relevant [1] and to discover unexpected shared func-
tions between those genes [3, 4]. One of the most widely
used databases for functional annotations is the Gene
Ontology (GO) [5, 6]. This database is highly regarded
both for its comprehensiveness and its unified approach
for annotating genes in different species to the same ba-
sic set of underlying functions [5]. In order to evaluate
the strength of connection between a gene signature pre-
dicted by an experimental system and the set of genes
that are annotated to a given biological function in this
database, most functional enrichment analysis tools rely
on set-overlap statistics [7]. Because these approaches
are subject to an increase in type I errors associated with
multiple hypothesis testing, corrections such as the Ben-
jamini, Bonferroni, and FDR are often also applied [8]
(discussed in more detail below).
Young et. al. recently pointed out that these stan-
dard statistical approaches are sometimes inadequate,
specifically when evaluating the functional properties of
gene-sets derived from RNA-seq data since these ex-
periments are prone to selection-bias due to variabil-
ity in gene length [9]. Despite the wide use of func-
tional analysis tools, however, little attention has been
∗contact: kglass@jimmy.harvard.edu
paid to whether or not the underlying properties of the
functional databases themselves may contribute to spu-
rious statistical results. For example, functional terms in
GO are related through a directed acyclic graph (DAG)
whose structure contributes to the heavy-tailed distribu-
tion seen in the number of gene annotations for individ-
ual terms [10]. In this work we investigate whether these
annotation properties lead to a bias in the results of tra-
ditional functional analysis methods. We find that the
significance level of the association between random gene
sets and functional terms in GO are positively correlated
with the number of annotations made to the genes in a
given gene set.
We also investigate the properties of experimentally-
derived gene signatures, as reported in the Gene Signa-
tures Database [11] and find that most signatures in-
clude a disproportionate number of highly annotated
genes. Furthermore, traditional overlap statistics find
significant associations between these signatures and ran-
domly constructed annotation sets. Consequently, we
propose a scheme, called Annotation Enrichment Anal-
ysis (AEA), that focuses on the overlap in annotations
between a set of genes and the set of terms belonging
to a branch of the GO hierarchy. By looking at annota-
tion overlap instead of gene overlap, our approach takes
into account the annotation properties of the Gene On-
tology. It effectively eliminates biases due to database
construction and highlights relevant biological functions
in experimentally-defined gene signatures. We also pro-
vide an analytic approximation to AEA that is able to
partially compensate for the biases we find using tradi-
tional approaches. Implementations of both approaches
are provided at http://www.networks.umd.edu.
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2There are many functional annotation databases that
have been developed in order to classify genes according
their various roles in the cell [12–16]. Here, we focus our
analysis on functional annotations made to the Gene On-
tology because of its wide use by many functional enrich-
ment tools (for example [1, 2, 17–19]). Since many of the
annotation properties of the Gene Ontology are shared
by other databases [10], we believe that the methods we
develop here could be applied to functional enrichment
analysis using other classification databases.
The Gene Ontology [5] takes the form of a directed
acyclic graph (DAG) in which “child” functional cate-
gories (“terms”) can be subclassified under one or more
other, more general categories, called “parent” terms, us-
ing “is a” and “part of” relationships. “Branches” in the
Gene Ontology can therefore be defined as sets of terms
that contain a parent term and all of its progeny. Note
that these branches will contain overlapping sets of terms
since each term can be a descendant of multiple ancestors
at each level of the DAG. Within this structure, genes
are annotated to a set of functional categories. These
annotations are transitive such that a parent term will
take on all the genes annotations associated with any of
its progeny [20]. Consequently, terms with many progeny
often contain many gene annotations whereas terms with
few progeny generally have fewer associated genes. Note
that since every parent term takes on the annotations of
its progeny, the number of unique genes annotated to a
parent term is the same as the number of unique genes
annotated to the branch defined by the parent term and
its progeny; however, the total number of annotations
made to any parent term with children is less than the
total number of annotations made to the corresponding
branch. “Biological Process,” “Molecular Function,” and
“Cellular Component” are the three most general terms
in GO, defining three independent branches such that ev-
ery other term can only belong to one of these three cat-
egories. As a consequence all genes in GO are annotated
to at least one, and often all three, of these categories.
Since we want to determine the influence of annota-
tion properties on functional enrichment analysis, espe-
cially in the context of experimental gene signatures in
commonly studied diseases such as cancer, we focus our
study on GO annotations that are associated with human
genes. With this in mind, we downloaded information
regarding gene-term annotations for human genes from
the Gene Ontology website (geneontology.org) and used
this data to construct a gene-term bipartite graph, rep-
resented as an nG × nT adjacency matrix, where nG is
the total number of genes and nT is the total number of
terms listed in the annotation file. In this matrix a value
of one indicates a known connection between the corre-
sponding gene and term, and a value of zero indicates
that the gene is not associated with that term.
In this bipartite graph many terms are only associated
with a small handful of genes, while some terms are as-
sociated with many genes. A histogram of the “degree”
of terms (k
(p)
t , or the number of genes annotated to term
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FIG. 1: The cumulative degree distributions of (a) genes and
(b) terms in human GO annotations.
p) reveals a heavy-tailed relationship (Figure 1(a)). In
contrast, a histogram of the “degree” of genes (k
(i)
g , or
the number of terms to which gene i is annotated) shows
that although some genes have many more annotations
than others, the distribution is not as skewed as the term
degree distribution. (Figure 1(b)).
The “Biological Process” ontology contains a signifi-
cant fraction of the total annotations. Although all three
ontologies are used in functional enrichment analysis, it
is common to focus on this ontology, both for its size
and because its members describe dynamical processes
performed by the cell. We will do the same in the follow-
ing analysis. The total number of annotations made to
the “Biological Process” ontology is 656783, originating
from 18930 genes to 10192 terms. Consequently, the av-
erage number of annotations made by an individual gene
is 43.2 and the average number of annotations made to
an individual term is 64.4. These values will be useful to
keep in mind, especially as we investigate the annotation
properties of gene signatures and of the terms for which
they are enriched.
The most widely used statistics for evaluating which
functional categories are enriched in a set of genes are
based on gene counts and include Fisher’s Exact Test,
the binomial test, and the chi-squared test [7]. Although
these statistics vary in exact implementation, they all
rely on the same basic underlying assumption that all
genes have an equal probability of being selected under
the null hypothesis. Of these tests, Fisher’s Exact Test
(FET) is the most common statistic and is used by many
of the most popular functional enrichment tools (see Ta-
ble 2 in [8]), and therefore we choose it to represent a
“typical” evaluation of gene set functional enrichment.
Although it is recognized that this statistic makes as-
sumptions in its null hypothesis that fail to reflect the
complex properties of the Gene Ontology, it is widely
regarded as a good guide in determining what types of
functions are represented in a given set of genes.
Since most functional enrichment analysis compares a
gene set to all the terms in GO, multiple-hypothesis test-
ing corrections are often applied to these p-values [8].
These corrections raise the value at which a compari-
son between a gene set and a GO term should be con-
3sidered significant. Commonly used multiple-hypothesis
corrections include the Bonferroni, Benjamini and the
False Discovery Rate. Of these, the Bonferroni is the
most conservative and adjusts the value at which a test
is considered “significant” by the number of tests made.
However, although this correction will change the criti-
cal value of individual tests, but will not affect the rank
ordering of these tests. In contrast, the False Discovery
Rate (FDR) adjusts the value at which a test is consid-
ered “significant” based on the rank of the predicted level
of significance. It will provides approximately the same
correction as the Bonferroni for the most significantly-
ranked p-values but will not adjust tests that are the
least-significant by rank. As a consequence, the rank
ordering of the significance can change slightly when us-
ing the FDR. For more details on how to calculate these
scores, see Methods.
2. RESULTS
2.1. Annotation Properties Influence the Results of
Functional Enrichment Analysis
We wished to determine the effect of annotation prop-
erties on functional enrichment analysis. First, we cre-
ated we created random gene sets with Ng = 200 mem-
bers each, but in which we controlled the total number of
annotations (Mg) made by the genes belonging to each
gene set, such that the average degree of the genes in the
set (kavg = Mg/Ng) varies from approximately 21 to 65,
or from around half to 1.5 times the expected average
degree of 43. Next, we also created random “branches”.
We note that because terms in GO are related via a hi-
erarchical DAG, they can often share many of the same
gene annotations. Therefore, our random “branches” are
composed of random selections of GO terms whose gene
annotations will collapse together such that their “faux”
parent term will have the same total number of gene an-
notations as a term that currently exists in GO. In other
words, each random “branch” will have the same num-
ber of unique genes annotated to it as a real GO branch,
but these gene annotations to the faux parent term will
be influenced by a cumulation of annotations made to
a random set of progeny terms. For details on how we
constructed these random gene sets and “branches” see
Methods.
As an initial test, we used our random gene sets to
evaluate how annotation bias might effect the enrichment
significance predicted in a functional enrichment test. To
do this we used FET to determine the enrichment of our
randomly constructed gene sets in GO terms from the
“Biological Process” ontology. Figure 2(a) shows the re-
sults for terms that have 200 or more gene annotations,
ordered based on their total number of gene annotations.
The trend is striking. Even though they have the same
number of members, gene sets with a higher number of
annotations are more enriched in GO terms compared to
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FIG. 2: The enrichment (measured by p-value) of 200 ran-
domly generated gene sets in annotations made to either
real GO branches or randomly constructed “branches”. The
branches are ordered based on how many genes are annotated
to the parent term (kt) and the gene sets are ordered based
on total the number of annotations (Mg) made by the 200
genes in that set. There is an obvious bias toward signifi-
cant enrichment between high degree gene-set/term pairs in
(a) Fisher’s Exact Test (FET), (b) even when using randomly
constructed “branches”; however this is correctly accounted
for using (c-d) Annotation Enrichment Analysis (AEA).
gene sets with a lower number of annotations. Branches
with an increased number of genes annotated to the par-
ent term (kt) also tend to be the most significantly en-
riched, especially in these “highly-annotated” gene sets,
consistent with that fact that the significance level pre-
dicted by a method such as FET is dependent on the
number of members in a given gene set. We point out
that although multiple-hypothesis corrections will suffi-
ciently raise a p-value such that either very few or no
false positives will occur, the biases themselves cannot
be overcome in this manner. A Bonferroni correction
will not chance the ordering of the p-values and the bias
will remain. Even an FDR correction, which can alter the
rank ordering of significance, is insufficient to overcome
this strong signal (see Supplemental Figure S1).
Next, we investigated what effect, if any, overlapping
annotations between GO terms might have on functional
enrichment analysis. Namely, we used FET to determine
the enrichment of our random constructed gene sets in
our random “branches”. Interestingly, the trend we ob-
served with real GO branches – that those with more
gene annotations to the parent term also tend to be en-
riched in “high-degree” gene sets – appears to be even
more pronounced when using random “branches” (Fig-
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FIG. 3: An outline of how Annotation Enrichment Analysis
(AEA) calculates the significance of association between a
given gene signature and the collection of terms that belong
to a branch in the GO hierarchy.
ure 2(b)). This suggests that part of the bias from FET
might result from overlapping annotations to GO terms.
2.2. Annotation Enrichment Analysis Corrects for
Annotation Bias
Clearly annotation properties of both genes and func-
tional categories can influence the results of functional
enrichment analysis. In order to mitigate these effects,
we suggest that instead of considering the overlap be-
tween two gene sets, as is traditionally done in functional
enrichment analysis, one instead considers the overlap
between annotations made to a gene set and a branch
of terms in the Gene Ontology. To accurately capture
the significance of annotation overlap we develop a ran-
domization scheme that preserves the structure of GO
annotations while calculating the probability of obtain-
ing a certain number of co-annotations between a gene
set and a GO branch. We call this approach Annotation
Enrichment Analysis (AEA) and illustrate it in Figure 3.
In this randomization is it useful to think of the Gene
Ontology as a bipartite graph (see Introduction). We be-
gin by determining Mg, the number of annotations to a
gene set, Mt, the number of annotations to the terms in a
GO branch, and Mgt, the number of annotations stretch-
ing between this gene set and branch. We then determine
a distribution for the expected number of co-annotations.
To do this we, simultaneous, randomly permute the order
of genes and terms while still preserving the original con-
nections from the GO bipartite graph. We then take an-
notations connected to the top random genes until we’ve
selected Mg annotations, and annotations connected to
the top random terms until we’ve selected Mt annota-
tions, and determine M˜gt, the number of edges in the
bipartite graph that extend between these top random
genes and top random terms. In the (fairly common) case
where selecting the top Mg/Mt annotations does not cor-
respond to selecting a whole number of genes/terms, we
take the top number of genes/terms whose total annota-
tions is closest to Mg/Mt, respectively. We repeat the
randomization process many times in order to determine
a distribution of values for M˜gt. We define a new p-value,
pA(Mgt) which reflects the probability that M˜gt ≥Mgt:
pA(Mgt) = P (M˜gt ≥Mgt). (1)
We determined the significance of all GO branches in
our randomly generated gene sets with AEA (using 104
randomizations), and created a heat map of these val-
ues as we had done for the significance values produced
using standard set-overlap statistics (Figure 2(a)). The
results of AEA are uniform across varying gene set de-
gree, demonstrating that AEA works well at eliminat-
ing annotation bias. We also determined the significance
of all random “branches” in our randomly generated
gene sets with AEA (104 randomizations), and created
a heat map of these values (Figure 2(b)). Whereas the
FET results looked nearly identical, the significance pre-
dicted by AEA is much lower for the randomly generated
“branches” compared to the real GO branches.
2.3. Experimental Gene Signatures are Often
Highly-Annotated
One of the most common applications of enrichment
analysis is to ascertain the functional properties of an ex-
perimentally determined set of genes. Although we have
demonstrated that AEA corrects for annotation bias with
randomly generated gene sets, we also want to know how
well this analysis can recapitulate biologically-relevant
results. With this in mind we downloaded signatures as
recorded in the Gene Signatures Database (GeneSigDB)
[11]. This database is a manual curation of previously
published gene expression signatures, focusing primarily
on cancer and stem cell signatures [21]. In the following
analysis we will use all 309 human signatures from this
database that contain at least 100 and less than 1000
genes that also are annotated to a term in the “Biologi-
cal Process” ontology.
First, to assess whether annotation bias might play
a role in evaluating the functional properties of these
gene signatures, we determined the average number of
annotations made to the genes occurring in each signa-
ture. Figure 4(a) shows the number of genes in a signa-
ture plotted against the average level of annotation for
each signature. The expectation for a random selection
of genes (the average number of annotations made to all
genes – see Introduction) is shown as a red line. The plot
suggests that many genes belonging to these signatures
are also more highly annotated in GO. Almost a third
(99) of the signatures have an average level of annota-
tion that is greater than any of our randomly generated
gene sets and all but four signatures have an average level
of annotation greater than expected by chance. Since we
5have shown that random gene signatures with these an-
notation levels encounter a bias in traditional functional
enrichment analysis, we believe these experimental sig-
natures are an appropriate biological set with which to
evaluate how AEA compares to FET when investigat-
ing and discovering the functions of genes contained in
experimental biological data.
Therefore, next we predicted the enrichment of all “Bi-
ological Process” GO terms in these signatures both by
traditional set-overlap statistics (FET) as well as with
AEA (106 randomizations). We first tested to see if the
two measures gave the same general results; in other
words, are the categories ranked highly by FET also
ranked highly by AEA and are the categories ranked
poorly by FET also ranked poorly by AEA. To this end
we selected the top 10% of terms based on their enrich-
ment score in FET and AEA to designate as “important”
according each to these measures. We compared this list
of terms to the list of terms that are “not important”
(in the bottom 80% of terms by rank) according to each
measure. The number of terms considered important in
AEA but not by FET versus the number of terms consid-
ered important by FET but not AEA for each signature
is plotted in Figure 4(b). Complete agreement between
FET and AEA on this plot is represented by a point
at (0, 0), and complete disagreement is represented by a
point at (1019, 1019). In order to see how annotation
properties influenced any differences, we colored signa-
tures based on the average level of annotation to their
member genes.
There is some agreement between AEA and FET, as
many points fall fairly close to the origin and, at most,
reflect only a 10% difference in identified “important”
terms. However, annotation bias is evident. In signatures
containing the highest levels of annotation, the terms
deemed most “important” by FET are more likely to be
considered “unimportant” according to AEA, and vice
versus. These results are consistent with the previous
analysis in random gene sets that showed a bias by FET
to place more significance between gene sets and terms
with a higher number of annotations (see Figure 2). It
also demonstrates that annotation bias is present when
evaluating experimentally-derived gene signatures and it
not an artifact of how we constructed our random gene
sets.
2.4. Annotation Enrichment Analysis Uncovers
Meaningful Biological Associations
Next, we investigated the specific biology that is high-
lighted using AEA and FET. We chose approximately
forty representative terms/signatures for each measure
by ranking according to the minimum enrichment score
each has across all signatures/terms and selecting the
most “significant” terms/signatures by this rank. For
AEA a few (981 out of 3149328 possible) term-signature
pairs have an estimated p-value of p < 10−6 after one mil-
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FIG. 4: Annotation properties of experimental gene signa-
tures. (a) The number of genes versus the average number of
annotations made to the genes in each signature. Genes from
signatures generally contain many more GO annotations than
one would expect if selecting genes randomly (red line). (b)
The number of terms that are considered important (top 10%
by rank) by one of the measures (either AEA or FET), but
not important (bottom 80% by rank) by the other, plotted
for each gene signature. The signatures are colored according
to the average level of annotation (kavg = Mg/Ng).
lion randomizations, therefore, when necessary, we broke
ties by the number of signatures/terms enriched in the
terms/signatures at this level. We performed hierarchical
clustering (using the “clustergram” function in Matlab
with default settings) on the terms and signatures se-
lected for each measure. The results are shown in Figure
5.
Clustering the FET results gives rise to a weak visual
segregation of terms and signatures into groups (Figure
5(a)). These groups highlight the relationship between
the gene signatures and several important biological pro-
cesses. For example, the FET clustering shows an enrich-
ment of cell-cycle related processes in breast cancer sig-
natures [22] and includes immune-related terms enriched
in immune gene signatures. These two groups, however,
account for only about half of the selected terms; the
clustergram also includes a number of functional cate-
gories related to “proteins” and “phosphorylation” that
are only enriched in a small number of signatures. From
this analysis we suggest that the results of FET might be
muddled by a signal driven by annotation bias, highlight-
ing either highly-annotated signatures or more general
biological processes.
In contrast, using AEA, distinct clusters of signatures
and terms emerge (Figure 5(b)). The first includes signa-
tures from immune-systems, lymphoma and leucocytes,
and is logically also enriched in terms such as “immune
system” and “response to stimulus” as well as terms re-
lated to “biological regulation”. Interestingly, one of the
breast signatures associated with this cluster [23] repre-
sents a list of genes defined based on immune response
in breast cancer and the stem cell signature [24] is from
a study on patients with systemic sclerosis, a type of
autoimmune disorder. In addition, the inclusion of a
protein-kinase signature [25] is interesting as MAP ki-
nases have been shown to play an important role in im-
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FIG. 5: Clustergrams representing enriched term-signature pairs. (a) A clustering of signatures and terms selected based on
their enrichment-score according to FET. These signatures include those reported in [23, 25, 27, 30, 34–62]. (b) A clustering of
signatures and terms selected based on their enrichment-score according to AEA. The signatures and terms break into several,
biologically distinct units. One is associated with immune-response, and includes signatures published in [23–25, 34, 35, 37, 39,
40, 63, 64]. A second includes signatures related to cellular-differentiation published in [27, 42, 44, 46, 65–70]. Another cluster
includes breast cancer signatures published in [51–54, 56–59, 61]. Finally three lymphoma [30, 62, 71] and a viral signature [31]
associated with proliferation are also included. The colorscales for the p-values were chosen to give approximately the same
red/green balance in each clustergram.
mune response [26].
Another cluster is enriched in categories such as “sys-
tem development” and “developmental process” and in-
cludes several signatures associated with stem cells or
identified based on their role in cellular differentiation.
It also includes a signature of oncogenes [27], as well as
a signature of homeodomain proteins, known to initiate
cascades of genes that in turn will induce cellular dif-
ferentiation into tissues and organs (e.g. [28, 29]). The
next cluster, associated primarily with breast cancer sig-
natures, shows a strong enrichment for terms related to
the cell cycle and cellular component organization, pro-
cesses known to be differentially regulated in breast can-
cer [22]. Finally, two lymphoma and one viral signature
that were identified based on cell proliferation (for ex-
ample, by association with Myc targeting [30, 31]) are
enriched for terms such as “cellular metabolic process.”
This is consistent with expectation since there is evi-
dence that a connection exists between proliferation and
metabolic pathways in cancer cells [32, 33].
2.5. Some Predictions Made by FET are Likely a
Consequence of Annotation Bias in Experimental
Gene Signatures
Finally, we also wanted to determine how database
construction might effect the results of functional en-
richment analyses using experimental gene signatures.
Therefore, we investigated the enrichment of experi-
mental gene signatures in our randomly constructed
“branches” and compared the results with that from real
GO branches. Briefly, for each evaluation, we deter-
mined the number of term-signature comparisons consid-
ered significant at several different thresholds and present
the results in Figure 6.
We were surprised to find that, using FET, there is
almost no difference between the number of significant
comparisons made using real GO branches and using the
randomly constructed “branches”. However, this phe-
nomena can be understood as follows. When calculating
the significance between two gene sets, FET assumes all
genes in those sets have an equal probability of being
chosen. This is a false assumption as some genes are ac-
tually more likely to be annotated to any given term in
GO. Since our random “branches” are constructed from
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FIG. 6: A plot of the number of term-signature comparisons deemed “significant” at various p-value thresholds. A dotted
line indicates only one comparison with a p-value less than or equal to the indicated threshold, and cases where no significant
comparisons were found for the corresponding p-value are indicated by a bar not exceeding this line. Evaluations using gene
annotations to GO branches are shown as solid colors, whereas evaluations using genes annotated to random “branches” are
striped.
actual GO annotations, these same “high-degree” genes
are also more likely to appear in annotations made to the
collection of terms defining each random “branch.” As
noted above, experimental gene signatures also include
an abundance of genes with higher levels of annotations.
Combined together, this bias means that these genes are
likely to be enriched in random sets of functional cat-
egories, just because their members have more annota-
tions overall. We believe this illustrates a flaw of FET
in that it will predict significant functional associations,
not because of biological signal, but as a result of a bias
in signature annotation properties.
Compared to FET, AEA finds overall fewer enriched
pairs at each threshold, but, unlike FET, finds no sig-
natures enriched in the random “branches”, demonstrat-
ing its ability to correct for annotation biases introduced
from the hierarchical relationships between those terms
in the ontology. These results give us confidence that
AEA is highlighting the connections between gene sets
and branches that are most likely to be truly biologically
relevant and is robust against biases introduced by an-
notation properties.
2.6. A Quantitative Approximation to Annotation
Enrichment Analysis Partially Corrects for
Annotation Bias
One significant strength of AEA is that it makes no
assumptions regarding the structure of gene-term anno-
tations; however, because it uses a randomization scheme
to estimate the null hypothesis, the precision of the esti-
mated p-values is dependent upon the number of random-
izations, and each run of the algorithm will give slightly
different results. Therefore, we sought an analytic ap-
proximation of AEA in order to overcome these limita-
tions.
Given that we want to estimate the significance of an-
notation overlap, one logical approach is to simply count
the number of annotations made to a gene set, the num-
ber of annotations made to a branch in GO, and the the
number of annotations extending between that gene set
and branch, and use the hypergeometric probability to
determine the significance of this overlap. We point out
that this approach makes the false assumption that an-
notations are independent, implying that a gene could be
annotated to the same term multiple times. Because of
this false assumption, it will not make as good of predic-
tions as the randomization protocol specified by AEA;
however, it can be computed quickly and without the
need for any randomization to generate a null hypothe-
sis.
Acknowledging that we are making some false assump-
tions regarding the structure of gene-term annotations,
we propose an analytic equation, Annotation Enrichment
Analysis Approximation (AEA-A). This approximation
makes use of the hypergeometric probability to calcu-
late the significance (or p-value approximating AEA,
pa(Mgt)) of overlap between annotations made to a given
gene set and branch in the GO hierarchy. Given Mg
annotations to a gene set, Mt annotations to terms be-
longing to a GO branch, and Mtot annotations made in
the GO ontology, the probability of finding Mgt or more
annotations in common between these two sets can be
written as:
pa(Mgt) = P (M ≥Mgt|Mg,Mt,Mtot)
=
min[Mg,Mt]∑
i=Mgt
(
Mt
i
)(
Mtot−Mt
Mg−i
)(
Mtot
Mg
) . (2)
We tested the performance of this approximation by
determining the functional enrichment of GO terms in
our randomly generated gene sets. The results of AEA-
A are uniform across varying gene set degree (see Sup-
plemental Figure S2), demonstrating that AEA-A works
well at eliminating annotation bias. However, the pre-
dicted p-values are often mis-leadingly low due to the
independence assumption. This limitation is evident in
analysis performed on the experimental signatures (Fig-
ure 6) – many more comparisons are deemed “significant”
at each threshold using AEA-A than either AEA or FET.
Furthermore, compared to AEA, the approximation is
8only partially able to discern between real GO branches
and random “branches”. Therefore, we conclude that
although this analytic approximation is conceptually ap-
pealing and has some advantages over FET, it does not
give results that are as discerning as AEA.
3. DISCUSSION
We have demonstrated that using traditional set-
overlap statistics, such as FET, to evaluate the func-
tional enrichment of gene sets is susceptible to produc-
ing false positives due to the annotation features of the
GO database. We offer a solution, Annotation Enrich-
ment Analysis, or AEA, that fully considers these prop-
erties, eliminating any potential annotation bias in the
predicted enrichment scores. The importance of using
this approach is highlighted by the fact that many pub-
lished gene-signatures include a large number of highly-
annotated genes. This is likely in part due to a non-
independence between identified signatures and func-
tional annotations, since genes that are involved in a
well-studied phenomena such as cancer are also more
likely to be frequently annotated in these databases. Al-
though it is possible that newly-derived gene signatures
may not exhibit the same level of annotation-bias as these
previously-published signatures, it is also very probable
that highly annotated genes are important in a wide vari-
ety of well-studied systems and will continue to show up
and influence the results of functional enrichment anal-
ysis on newly generated gene sets. In light of this we
suggest using our approach alongside or in place of other
traditional measures, especially for gene signatures that
are known to contain significantly more or less annota-
tions than one would expect by chance. We believe that
AEA will allow biologists to better interpret the func-
tional roles of genes identified as important in their ex-
perimental system.
4. METHODS
4.1. Calculating Functional Enrichment using
Set-Overlap Statistic
In this analysis we use Fisher’s Exact Test (FET) to
evaluate biases in the performance of “traditional” func-
tional enrichment analysis. FET is related to the hyper-
geometric probability and can be used to calculate the
significance, or p-value estimated using FET (pF (Ngt))
of an overlap between two independent sets. For exam-
ple, given a gene set containing Ng genes, a GO term
with kt annotations, and Ntot total genes annotated in
GO, the probability that Ngt or more genes belong both
to this gene set and are annotated to the GO term can
be calculated as:
pF (Ngt) = P (N ≥ Ngt|Ng, kt, Ntot)
=
min[Ng,kt]∑
i=Ngt
(
kt
i
)(
Ntot−kt
Ng−i
)(
Ntot
Ng
) . (3)
Together with the FET, we also sometimes report the
False Discovery Rate (FDR) in order to account for any
potential Type I error. The FDR can be calculated as:
β = αn/r (4)
where, α is the value at which an individual test was
previously considered significant, β is the value at which
an individual test should be considered significant, given
n repetitions of that test, and r is the rank of the test.
4.2. Constructing Biased Random Gene Sets and
Random “Branches”
In order to investigate potential bias due to the annota-
tion properties of gene sets, we constructed random gene
sets with the same number of members, but with varying
amounts of annotations made by those members. Each
set with a desired total number of annotations, Mg, was
created by first randomly selecting Ng genes. We then
randomly selected one gene in this gene set (gene i) and
one gene not in the gene set (gene j). If replacing gene i
with gene j caused the total number of annotations made
by genes in the gene set to approachMg, we replaced gene
i with gene j with a high probability (p = 0.95), but if the
replacement caused the average degree of the gene set to
move farther away from Mg we replaced gene i with gene
j with a low probability (p = 0.05). This swapping con-
tinued until the total number of annotations made by the
gene set was within 0.1% of Mg. In this way we created
200 gene sets with Ng = 200 genes each, but whose av-
erage degree (kavg = Mg/Ng) varies from approximately
21 to 65.
We also constructed sets of random GO terms that
represent random “branches”. Specifically, to mimic a
branch in the GO DAG that has a parent term with kt
gene annotations, we randomly ordered all the terms in
GO and selected the top Nt terms until the number of
unique genes annotated to those Nt random terms (k
′
t)
is within a small percentage of kt (|kt − k′t|/kt < 0.01).
In the case where selecting both Nt and Nt+1 terms were
within this limit we chose Nt to minimize the absolute
difference between kt and k
′
t. If selecting the top Nt
terms did not lead to a situation within this limit, we
reshuffled the terms and selected the top Nt terms in
this new list, repeating until a suitable random collection
of terms could be chosen. In this way we created 10192
random “branches” with approximately the same number
of unique genes annotated to each as to real GO branches,
but in which the genes annotated to the faux parent term
are influenced by a cumulation of annotations made to a
random set of progeny terms.
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FIG. S1: The FDR-corrected significance of GO terms in 200
randomly generated gene sets. The terms are ordered based
on how many genes are annotated to the term (kt) and the
gene sets are ordered based on total the number of annota-
tions (Mg) made by the 200 genes in that set. Although the
p-values are sufficiently high that few, if any, false positives
occur, there is still an obvious bias toward significant enrich-
ment between high degree gene-set/term pairs.
Random Gene Sets (<k>→)
(←
 
k t)
 G
O 
Br
an
ch
es
 
 
−log
10
 p−value
0
1
2
3
4
(a)AEA-Approximation (GO
Branches)
Random Gene Sets (<k>→)
(←
 
k t)
 R
an
do
m 
"B
ran
ch
es
"
 
 
−log
10
 p−value
0
1
2
3
4
(b)AEA-Approximation
(random “Branches”)
FIG. S2: The significance of GO branches and random
“branches” in 200 randomly generated gene sets according to
AEA-A. The branches are ordered based on how many genes
are annotated to the parent term (kt) and the gene sets are
ordered based on total the number of annotations (Mg) made
by the 200 genes in that set. As with AEA, AEA-A (a) suc-
cessfully eliminates the annotation bias associated with high
degree gene-sets and (b) predicts relatively fewer significant
associations with random “branches”.
